Maternal serum Alpha-fetoprotein Level at 12, 22 and 32weeks’ gestation in screening for pre-eclampsia
Article Sidebar
Main Article Content
Abstract
Pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality. Alpha_fetoprotein is measured in pregnant women, as a screening test for pre-eclampsia.This study aimed to examine the maternal serum alpha-fetoprotein at 12, 22 and 32 weeks ’gestation in singleton pregnancies and its performance as a screening test for Pre eclampsia. The study designed as prospective (Cohort) study, it was conducted in Obstetrics department in Salah AL Din Teaching Hospital, from the period of the 15th of December 2016 to the 1st of July 2017. Ninety six pregnant women at first trimester participated in the study, followed up prospectively sixty three of them was attended a second test in second trimester and seventy five of them was attended a third test in a third trimester. The mean age of the studied group was 27.1 ± 5.8 (range: 17-30) years .It had been observed that the mean level of Alphafetoprotein was increased and the mean Multi of Median( MoM) was significantly reduced with advanced gestational age., there are highly significant differences at the different check-points in both mean and MoM, of the maternal alpha-fetoprotein. The mean alpha-fetoprotein level was higher in pre-eclampsia group compared to non-preeclampsia in all of the three testing points. The Comparison of mean alpha-fetoprotein levels of pre-eclampsia vs. non-preeclampsia women revealed that the mean, alpha-fetoprotein level was higher in pre-eclampsia group compared to non-preeclampsia in all of the three testing points, alpha-fetoprotein level at the second test was the better than the first and third test.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Khan, KS., Wojdyla, D.; Say L. et al . (2006). WHO analysis of causes of maternal death: a systematic review. Lancet ; 367(9):1066-74.
[2] Keith, E. (2012). Dewhurst' Textbook of Obstetrics and Gynaecology. Wiley Blackwell. ; (8): 107.
[3] Rodie, V. A.; Freeman, DJ.; Sattar, N. et al. (2004). Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis.; 175: 189 - 202.
[4] Sebire NJ, Jolly M, Harris JP. et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord. 2001; 25:1175-1182.
[5] Middleton, P.; Crowther, C.A.; Simmonds, L. et al : (2010). Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev CD008540.
[6] Ichikawa, E. ; Kuriyama, S.; Yuji, J. et al. (2006). Further resolution of alpha-fetoprotein glycoforms by two dimentional isoelectric focusing and lectin affinity electrophoresis. Electrophoresis; 27: 3480- 7.
[7] Caughey, AB.; Stotland, NE.; Washington, AE. et al. (2005). Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol. ; 106:156-161.
[8] Duckitt, K. and Harrington, D. (2005). Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ.; 330:565.
[9] Triche, EW.; Saftlas, AF.; Belanger, K.. et al (2004). Association of asthma diagnosis, severity, symptoms, and treatment with risk of preeclampsia. Obstet. Gynecol.; 104: 585-593.
[10] Murray, M.J. and J.C. Nicholson. Alpha-Fetoprotein. Arch Dis Child Educ Pract Ed, 2011. 96(4): 141-7.
[11] Dashe JS, Twickler DM, Santos-Ramos R, et al. (2006). AFP detection of neural tube defects and the impact of the standard ultrasound. Am. J. obstetric. gynecology; 195: 1623.
[12] Gerald J. (2004). Mizejewski. Biological Roles of Alpha-fetoprotein during Pregnancy and Perinatal Development, Experimental Biology and Medicine; 229: 439- 63.
[13] Moldogazieva NT, Terent'ev AA and Shaitan KV.(2005). Relationship between structure and function of alpha-fetoprotein: conformational status and biological activity. Biomeditsinskaia khimiia.; 51: 127-51.
[14] Long L, Davidson JN and Spear BT.(2004). Striking differences between the mouse and the human alpha-fetoprotein enhancers. Genomics; 83:694 – 705.
[15] Carty DM, Delles C, Dominiczak AF (2010). Preeclampsia and future maternal health. J. Hypertens; 28:1349-1355.
[16] Freeman DJ, McManus F, Brown EA. et al. (2004). Short- and long-term changes in plasma
inflammatory markers associated with preeclampsia. Hypertension ; 44:708-714.
[17] Kiran TSU, Bethel J, Bhal PS.(2005). Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J, Obstet. Gynaecol.;25(3):253-6.
[18] Wright D, Syngelaki A, Akolekar R et al. (2015). Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol; 213: 62: 1-10.
[19] Tranquilli AL, Dekker G, Magee L et al.(2014). The classication, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. hypertens Pregnancy.; 4:97-104.
[20] Dayal Meena, Gupta Parul. (2011). Role of Second Trimester Maternal Serum Markers as Predictor of Preeclampsia. The Journal of Obstetrics and Gynecology of India. 38 – 41
[21] Razieh Dehghani–Firouzabadi, Naeimeh Tayebi. (2010). The association between second trimester Maternal serum Alpha fetoprotein in 14-22 weeks and adverse pregnancy outcome. Acta Medica. Iranica; 48: 4.
[22] Kuo PL, Lin CC, Lin YH, Guo HR. (2003). Placental sonolucency and pregnancy outcome in women with elevated second trimester serum alpha-fetoprotein levels. J. Formos. Med. Assoc.; 102(5):319-25.
[23] Huerta-Enochian G, Katz V, Erfurth S. (2001). The association of abnormal alpha-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am. J. Obstet. Gynecol ; 184(7):1549-53.
[24] Tikkanen M, Hämäläinen E, Nuutila M, Paavonen J, Ylikorkala O, Hiilesmaa V. (2007). Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption. Prenat Diagn.; 27(3): 240-3.
[25] Walter DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. (1996). The association between maternal serum alpha fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet. Gynecol.; 88(5): 816-22.
[26] Williams MA, Hickok DE, Zingheim RW, Luthy DA, Kimelman J, Nyberg DA, et al.(1992). Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. Am. J. Obstet. Gynecol.;167(4 Pt 1):1032-7.
[27] Bredaki F.E, Mataliotakis M, et al.(2016). Maternal serum alphafetoprotein at 12, 22 and 32 weeks gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol; 47: 466-71.
[28] Jacobsson B.(2004). Advanced Maternal age and adverse perinatal outcome. Obstet. Gynecol. 104(4): 727–33.
[29] Bodnar LM, Ness RB et al. (2005). The risk of preeclampsia rises with increasing pre-pregnancy body mass index. Annals of Epidemiology.; 15: 475–82.
[30] Singhal SR, Deepika. et al. (2009). Maternal and perinatal outcome in severe pre eclampsia and eclampsia. J. South Asian Fed Obstet. Gynecol;1: 25–8
[31] Tikkanen M, Hämäläinen E, Nuutila M, Paavonen J, Ylikorkala O, Hiilesmaa V. (2007). Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption. Prenat. Diagn; 27(3):240-3.